Release Date: November 18, 2022
Expiration Date: November 18, 2023
Activity Overview
The cutaneous symptoms and pain of hidradenitis suppurativa (HS) place a significant burden on patients. Emerging treatments continue to build the arsenal of therapeutic options. However, comorbidities associated with the disease complicate management and underscore the value of a multidisciplinary care approach, including medical and psychosocial support systems. The establishment of treatment goals through patient-focused, multidisciplinary care will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.
Target Audience
This educational activity is directed toward dermatologists, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the treatment and management of HS. Primary care providers and women’s health professionals who may be involved in the first-line diagnosis of HS are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop multidisciplinary care plans for patients with HS based on shared goals of therapy
Colleen Cotton, MD, FAAD
Assistant Professor
Division of Dermatology
Children’s National Hospital
Washington, DC
Disclosures: Grant/Research Support: Regeneron, Sanofi, Target RWE, Eli Lilly and Company; Consultant: Pierre-Fabre; Other: subinvestigator for investigational research: AbbVie, Arcutis Biotherapeutics.
Raj Chovatiya, MD, PhD, FAAD
Assistant Professor of Dermatology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Grant/Research Support: Castle Biosciences; Consultant: AbbVie, Arcutis, Arena, argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, L'Oréal, National Eczema Association; Speaker’s Bureau: AbbVie, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
